Givinostat Approved for Duchenne Muscular Dystrophy Treatment

Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder predominantly affecting males, leading to a progressive loss of mobility. This condition arises from mutations in the dystrophin gene, which is crucial for muscle fiber integrity. The absence of functional dystrophin renders muscle fibers more vulnerable to damage, resulting in increased levels of histone deacetylases (HDAC) in muscle cells. This accumulation blocks the activation of essential genes responsible for muscle maintenance and repair.

As the disease progresses, muscle fibers undergo degeneration, being replaced by scar tissue and fat. This deterioration leads to worsening muscle weakness, difficulties in walking, and ultimately, loss of ambulation. Additionally, the heart and respiratory muscles are affected over time, contributing significantly to premature mortality.

Givinostat, an HDAC inhibitor, has emerged as a potential therapeutic option for DMD. It is designed to modulate the unchecked activity of these enzymes that contribute to the disease's progression. Research indicates that Givinostat can reduce muscle fiber damage, chronic inflammation, fibrosis, and fat deposits. Importantly, its mechanism of action is independent of the specific mutation in the dystrophin gene that causes DMD.

The medication has been approved for use in ambulatory patients aged six and older, in conjunction with corticosteroid treatment. The dosing regimen is weight-based and involves administration twice daily. Givinostat is available as a suspension that requires thorough shaking before use to ensure proper dosage. It should not be mixed with fluids and is advised to be taken with food to mitigate its bitter taste.

Before initiating treatment, baseline platelet and triglyceride levels must be assessed. Patients with a platelet count below 150 x 10⁹/l cannot begin Givinostat therapy. Regular monitoring of these levels during treatment is essential to determine if dose adjustments are necessary.

The prescribing information also highlights the need for an electrocardiogram (ECG) at the start of treatment for patients with underlying heart conditions or those on medications that may prolong the QT interval.

Commonly reported side effects include diarrhea, abdominal pain, thrombocytopenia, vomiting, hypertriglyceridemia, and fever. Awareness of these potential adverse effects is crucial for managing patient care effectively.